Contraceptive Efficacy and Safety of 52 mg Levonorgestrel-Releasing Intrauterine Systems During Years 6–8 of Use: Data From the Mirena Extension Trial [A13]. (May 2022)

• Record Type: Journal Article
• Authors: Jensen, Jeffrey T.; Lukkari-Lax, Eeva; Schulze, Andrea; Baisden, Kristie W.; Serrani, Marco; Kroll, Robin
• Is Part Of: Obstetrics and gynecology. Volume 139(2022)Supplement 1
• Page Start: 4S
• Page End: 4S
• Publication Date: 2022-05
• Subjects: Obstetrics -- Periodicals; Gynecology -- Periodicals; 618
• DOI: 10.1097/01.AOG.0000826388.11789.c1
• Languages: English
• ISSNs: 0029-7844

Abstract

Abstract : INTRODUCTION: The Mirena Extension Trial (MET) evaluated efficacy and safety of 52 mg levonorgestrel-releasing intrauterine systems (LNG-IUS, Mirena) during extended use. METHODS: MET was a multicenter, single-arm US study enrolling women aged 18–35 years who were current users of 52 mg LNG-IUS for 4.5–5 years. Institutional review board approval was obtained for all centers. Contraceptive efficacy (Pearl Index, PI) of 52 mg LNG-IUS beyond 5 years up to 8 years of use was assessed. RESULTS: Of 362 participants starting year 6, 243 entered year 8, with 346 included in the year 8 primary analysis set (PAS, all participants aged 36 years or less at end of year 8). Mean (standard deviation) age for the year 8 PAS was 29.2 (±2.9) years and 50.9% were parous. Two pregnancies occurred (both with device in situ): one of undetermined location that spontaneously resolved in year 6 and one ectopic in year 7. For years 6–8, the 3-year PI (95% confidence interval) was 0.28 (0.03–1.00), with an estimated pregnancy probability of 0.68% (0.17–2.71). PIs for years 6, 7, and 8 were 0.34 (0.01–1.88), 0.40 (0.01–2.25), and 0.00 (0.00–1.90), respectively. Treatment-emergent adverse events were reported in 249/362 participants (68.8%) and were related to 52 mg LNG-IUS in 65 (18.0%). The discontinuation rate was 38.4% (139/362), most commonly due to wish for pregnancy (12.2%, 44/362). At end of year 8, 220/223 (98.7%) were satisfied with 52 mg LNG-IUS. CONCLUSION: 52 mg LNG-IUS, initially approved for 5 years, maintains high contraceptive efficacy, user satisfaction, and a favorable safety profile through 8 years of use.